YahooOctober 21, 2026 at 9:00 AM NY6 Days Ago
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
